Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Age 18-70 years

• Diagnosis of RA for ≥6 months

• Swollen or tender joint or ESR >ULN. Subject must be on stable doses of MTX

• Women of Childbearing Potential

Exclusion Criteria:

• Serum transaminase levels >ULN

• CK>ULN

• Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline

• Use of H2 blockers or Proton Pump inhibitors while on study